Skip to main content

Table 1 Baseline characteristics in predicted 10-y ASCVD risk (n = 4057)

From: External validation of pooled cohort equations using systolic blood pressure intervention trial data

  < 5% 5–7.5% 7.5–10% > 10%
Patients no. (%) 165 (4.0) 319 (7.9) 447 (11.0) 3126 (77.0)
Age, mean (SD) 55.1 (3.7) 57.6 (4.4) 59.6 (5.1) 66.4 (7.6)
African-Americans, no. (%) 43 (26.0) 113 (35.4) 198 (44.3) 1249 (40.0)
Men, no. (%) 26 (15.8) 103 (32.3) 199 (44.5) 2139 (68.4)
Systolic blood pressure, mean (SD) (mmHg) 130.0 (15.1) 134.1 (14.0) 134.7 (13.7) 142.8 (15.5)
Anti-hypertensive medication, no. (%) 146 (88.5) 262 (82.1) 370 (82.8) 2726 (87.2)
TC, mean (SD) (mg/dL) 207.5 (33.7) 203.5 (32.9) 200.0 (31.5) 201.1 (31.4)
HDL-C, mean (SD) (mg/dL) 57.4 (18.1) 55.4 (14.9) 54.1 (15.5) 53.0 (15.0)
LDL-C, mean (SD) (mg/dL) 125.2 (26.9) 124.3 (27.6) 122.2 (26.7) 122.9 (27.2)
  1. TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol